https://www.selleckchem.com/products/azd9291.html
In this review, we appraise the evidence surrounding the use of locoregional therapies in treating patients with CCA and CHC.Background We assessed whether serial ctDNA monitoring of plasma and saliva predicts response and resistance to osimertinib in EGFR-mutant lung adenocarcinoma. Three ctDNA technologies-blood-based droplet-digital PCR (ddPCR), next-generation sequencing (NGS), and saliva-based EFIRM liquid biopsy (eL-were employed to investigate their complementary roles. Methods Plasma and saliva samples were collected from pati
Like
Comment
Share
